Eli Lilly’s revenue growth is mainly due to its weight-loss and obesity franchise, blockbuster drugs like Mounjaro, Zepbound, and new developments such as the oral GLP-1 drug Foundayo and the pipeline drug Retatrutide, which drives significant investor focus.

Source link

Discover more from Occasional Digest

Subscribe now to keep reading and get access to the full archive.

Continue reading